Genetic Information for Families After Tumor Testing Study

The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer predisposition gene.

NCT Number	NCT07517666
Lead Sponsor	Abramson Cancer Center at Penn Medicine Collaborators: Emory University, Baylor College of Medicine, Fox Chase Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute, Ann & Robert H Lurie Children's Hospital of Chicago
Conditions	Cancer
Enrollment	100 participants
Start Date	2026-07-15
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-29